



## **Novel Mode Of Actions (MOAs) Of Marine Cardioactive Biomolecules (MCBs)**

**Avanendra Tiwari**

Department of Pharmaceutical Sciences  
Sardar Bhagwan Singh Post Graduate Institute of Biomedical Sciences and Research,  
Dehradun, Uttarakhand, India

**Dr. LUV Kush**

Department of Pharmaceutical Sciences  
Sardar Bhagwan Singh Post Graduate Institute of Biomedical Sciences and Research,  
Dehradun, Uttarakhand, India

***Abstract:***

*MCBs have antianginal, antiarrhythmic, antihyperlipidemic, antihypertensive and cardiotonic types of bioactivities. MOAs of MCBs followed the basic cardiopharmacological mechanisms. The structural uniqueness of Autonomium chloride, Anthopleurine A, marine toxins and nucleosides imparted new clues of mechanisms. The stereoselective drug action of Octopamine was topographically rationalized.*

### **1.Introduction**

Modern or 20<sup>th</sup> century development of advanced medicinal chemistry which is equivalent to molecular pharmacology for the discovery and designing of novel therapeutic agents have elegantly emerged with great success. Marine biomolecules have secured distinctions at therapeutic front. It encouraged us to gauge the cardioactive potential of marine biomolecules. The cardioactive biomolecules are anionic (acidic) and cationic (basic), therefore they have ionic character.

Recent development in marine pharmacology has explored biomedical potential of cardioactive marine biomolecules<sup>3</sup>. Antianginal, antiarrhythmic, antihypertensive, cardiotonic activities are encountered in MCBs.

### **2.Theoretical Methodology**

MOAs are delineated for rationalizing the roles of their structural uniqueness in drug action.

- Antianginal MCBs- They should have vasodilatory effect and are useful in coronary heart disease. Ca<sup>++</sup> channel antagonists block the L-type Ca<sup>++</sup> channels specifically present in heart and vascular smooth muscles. They are potent arteriolar vasodilators so effective in antianginal therapy.
- Omega-3 fatty Acids<sup>4,5</sup>-Eicosapentaenic acid (EPA) and Docosahexaenoic acid (DHA) (omega3-fatty acids) are conventionally formulated in fish oil capsule. They have cardioprotective effect in coronary heart disease because they decrease creatine kinase, lactate dehydrogenase and serum triglycerides. Their antiatherogenic effect is therapeutically beneficial as they decrease platelet aggregation. 2,2 dimethyl EPA is very potent. This enhances fatty acyl CoA oxidase action (beta oxidation).
- Antiarrhythmic MCBs- Antiarrhythmics modify and restore normal cardiac rhythm. Arrhythmias are due to disorder of electrical impulse formation by disturbances in impulse conduction through the myocardium. They act by blocking Na<sup>+</sup>, K<sup>+</sup>, Ca<sup>++</sup> ion channels. Voltage gated Na<sup>+</sup> channel blockers reduce the excitability of nodal regions of heart. They prevent Ca<sup>+</sup> mediated depolarization in SA-node and Purkinje fibres.
- Omega-3 fatty Acids (EPA and DHA)<sup>4</sup>

- They are potent inhibitors of voltage gated  $\text{Na}^+$  channels and have stabilizing effect on myocardium; therefore, they are useful in ventricular dysrhythmias. EPA and DHA prevents calcium preload by maintaining the activity of L-type calcium channels during periods of stress and enhance activity of cardiac microsomal  $\text{Ca}^+/\text{Mg}^{++}$  ATPase.
- Saxitoxin and Tetrodotoxin<sup>2,6-10</sup>
  - Marine toxins sensitive  $\text{Na}^+$  channels are present in the mammalian heart. They are selective blockers of voltage gated  $\text{Na}^+$  channels and cause no damage in action potential. Their receptor site is pore site 1, therefore are also known as “poreblockers”. Pore is made of large alpha subunits and small beta subunits. TTX and STX bind to site 1 located at extracellular pore opening of the ion channel.
  - TTX is amphoteric with unique tricyclic structure. It has both cationic (guanidine) and anionic (acid-hydroxyl) groups. The positively charged guanidium group interacts with negatively charged carboxylic group at pore of  $\text{Na}^+$  channel on extracellular side of plasma membrane.
  - STX is also tricyclic but has two guanidinium moieties.
- Antihyperlipidemic MBCs : They are hypolipidemic, and lipid regulators.
- Eckol<sup>11</sup>- It decreases triglycerides, total cholesterol, and LDL-C which are attributed to antihyperlipidemic effect.
- Antihypertensive MCB's<sup>2,3</sup> : Antihypertensives act by lowering the sympathetic tone or vasopressor activity. They also inhibit biosynthesis of Octapeptide, mediated by angiotensin converting enzyme in nephron. They block release of nitric oxide and ET 1 factor from active endothelium.
- Marine peptides<sup>12</sup>- They are ACE inhibitory peptides. They inhibit angiotensin-1 converting enzyme.
- Prostaglandins<sup>13</sup> – Participate in antihypertensive action by inhibition of angiotensin converting enzyme (ACE) and angiotensin type 1 (AT 1) Receptor antagonist.

- Phlorotannins<sup>5,11</sup> - They are phenolic compounds and formed the polymerization of phloroglucinol (=1,3,5-hydroxybenzene). They form a complex with protein and glycoproteins to inhibit ACE activity. It involves sequestration of the enzyme metal factor  $Zn^{2+}$  ion.
- Marine nucleosides<sup>2</sup>- Adenosinergic<sup>14</sup> and purinergic receptors<sup>15</sup> are targets for caffeine, adenosine and marine nucleosides. Adenosine is cardioprotective nucleoside which signals the activation of  $A_3$ -subtype Rs (seven-transmembrane alpha helices) for
  - Preservation of ATP levels
  - Stimulation of glycolysis
  - Limitation of oxygen demand
  - The functional role of purines and pyrimidines acting on purinergic Rs (Subtype P2) are implicated in the regulation of heart. ATP; UTP and UDP have cardioprotective roles.
- Marine nucleosides<sup>3</sup> (Spongosine, Doridosine, and Spongouridine) have close structural resemblances with adenosine and guanosine, therefore their interactions with adenosine Rs and purinergic Rs exhibited cardiovascular effects. They are:
  - Decreased heart rate and force of cardiac contractibility.
  - Negative inotropic effect.
  - Vasodilation
  - Enhanced coronary blood flow.
    - Their potencies in increasing vasodilation and coronary flow are:
    - Adenosine>Spongosine>Isoguanosine>Dridosine (most potent hypotensive)
- TTX<sup>6</sup>-Reduction in arterial blood pressure results from a reduced total peripheral resistance (TPR) and reduced cardiac output and vasomotor tone.
- Cardiotonic MCB's<sup>2</sup> – Cardiotonics have therapeutical value in congestive heart failure (CHF) or myocardial infarction. They increase the contractile force of the heart and have positive inotropic properties. They improve cardiac output and oxygen consumption per minute, thus cardiac efficacy is improved.

Haemodynamically kidney and heart have interdependent physiological relationship. The enhanced renal blood flow decrease ventricular preload and edema fluid.

- Halenaquinol<sup>16</sup>- It inhibits membrane transport enzyme  $\text{Na}^+ \text{K}^+$  ATPase SAR studies found that this inhibition is dependent on naphthohydroquinone fragment of the structure.
- Xestoquinone<sup>17,18</sup>- enhancement of intracellular cyclic AMP and  $\text{Ca}^{2+}$  influx across myocardial membrane impart cardiotoxic response. The strong inotropic activity is due to inhibition of  $\text{Na}^+ \text{K}^+$  ATPase.
- Autonomium chloride<sup>2,3,19</sup>- Autonomium chloride has dual adrenergic and cholinergic actions.




Figure 1

- Anthopleurine-  $\text{A}^3$ : potent positive inotropic effect, without chronotropic action. It is claimed that translocation of intracellular  $\text{Ca}^{2+}$  rather than extracellular influx of  $\text{Ca}^{2+}$  may be involve in MOA of APA. It is 200x more potent than DIGoxin, AP-A does not effect  $\text{Na}^+ \text{K}^+$  ATPase but has direct action on cardiac muscles and increase myocardial contractibility
- Octopamine<sup>2,20</sup>- Octopamine is a chiral marine biomolecule. It shares phenylethyl amine side chain of adrenomimetics (Norepinephrine and ephedrine).The structural similaritywith norepinephrine, and ephedrine imparted adrenoceptor

agonism with mixed MOA's. Octopamine is mixed adrenomimetic, because it causes activation of adrenoceptors (NE) and release of catechol amines from storage sites or inhibition of their uptake (ephedrine).

## 2. Discussion And Result

The basic principles of cardiovascular bioactions are followed by MCBs. The uniqueness of their MOAs are :-

- Autonomic nervous system (ANS) regulates cardiovascular physiology. Autonomium chloride mimics adrenergic and cholinergic neurotransmitters at structural level, for balancing normal cardiac functionality.

This is attributed to interatomic similarity with acetylcholine and phenolic and ethylenic similarity with adrenaline. Possibly it may balance cholinergic and adrenergic systems in CNS for normal cardiovascular physiology.

- Anthopleurine A is 200x times more potent than Digoxin, the classical feature of digitalis-strophanthus type of cardenolides are invalidated by MCB. It has peptide structure which has no effect on  $\text{Na}^+$ ,  $\text{K}^+$  ATPase but directly acts on cardiac muscle and enhance myocardial contractibility.
- Saxitoxin and Tetrodotoxin act as “ Pore blockers” at site 1 of voltage gated sodium channels, without any change in action potential.
- Marine nucleosides interact with adenosinergic and purinergic Rs, producing negative inotropy, vasodilation and coronary flow, which are therapeutically useful in cardiac ailments.
- Octopamine is chiral name marine biomolecule has mixed action of adrenomimetics.

The natural D(-) isomer is 3x more potent than L (+). This stereoselectivity can be explained in the following manner.

### 2.1. Interaction Of Octopamine Isomers With Adrenoreceptors




Figure 2




Figure 3

The D(-) isomer has more binding sites than L(+), therefore it is more active.

### 3. Conclusion

The structural uniqueness of MCBs shared basic MOAs of cardiovascular drugs. Their MOAs exhibited more than one cardiac activity at therapeutic level. Marine novel

chemical entities have great potential for the therapeutical exploration in cardiac vascular medicines.

#### **4.Acknowledgement**

The authors express their thankfulness to Shri Nitesh Kumar Mishra for helping in preparation of manuscript.



---

**5.Reference**

1. Alphonse Kelecom,1991,Marine Organism: An alternate Source of Potentially Valuable Natural products, Mem.,Inst. Oswalo Cruz, Rio de Janeiro, vol. 86, Supp ii, 99-106
2. Ashutosh Kar, 2007. Pharmacogony and Pharmacobiotechnology
3. Pushkar N.Kaul (1982). Biomedical Potential of Sea pure & Appl. Chem., Vol. 54, No.10,pp.1963-1972
4. Ali Aberoumand,(2010). The effects of Fish Oil And Marine Omega-3 Fatty Acids on Human Health. World Journal of Fish and Marine Sciences2(3);226-231
5. Jing X.Kang (1996) Antiarrhythmic Effects of Polyunsaturated Fatty Acids; Circulation; 94: 1774-1780 ©1996 American Heart Associate, Inc
6. Thomas Zimmer, (2010) Effect of Tetrodotoxin on the Mammalian Cardiovascular System, Mar Drugs.; 8(3): 741-762
7. Daly,J.W.2004 J.Nat. Prod.,67,1211
8. Schantz,E.J; Mold, J.D.; Stanger, D.W.; Shavel, J.; Riel, F.J.; Bowdwn, P.; Lynch, J.M.; Wyler, R.S.; Riegel, B.;Sommer,H.J. Am.Chem.Soc.1957,79,5230
9. Stommel, E.W.; Watters, M.R. Curr. Treat. Options. Neurol. 2004,6,105
10. Lau, F.L.;Wong, C.K.; Yip, S.H.J. Accid. Emerg. Med. 1995,12,214
11. Hyun Ah Jung, Sook Kyung Hyun, Hyeung Rak Kim and Jae Sue Choi, (2006), Fisheries Science,72,1292-1299
12. Isuru Wijesekara and Se-Kwon Kim 2010, Angiotensin-I- Converting Enzyme (ACE) Inhibitors From Marine Resources: Prospects in the Pharmaceutical Industry. Mar Drugs.; 8(4): 1080-1093
13. Iyer, Shridhar N,Yamada, Kazuo; Diz, DebraI.; Ferrario, Carlos M.; Chappell, Mark C. 2000. Journal of Cardiovascular Pharmacology; Volume 36. Issue 1. Pp 109-117
14. Beverly A. Rothermel and Joseph A. Hill. 2008, Adenosine A3 Receptor and Cardioprotection: Enticing, Enigmatic, Elusive. Circulation 118:1691-1693
15. David Erlinge & Geoffrey Burnstock 2008. P2 receptors in cardiovascular regulateon and disease. Purinergic Signalling 4:1-20
16. Gorshkove, I.A., Gorshkov, B.A., Fedoreev, S.A., Shestak, O.P., Novicov, V.L., Stonic, V.A., 1999a. Inhibition of membrane transport ATPase by halenaquinol, a

natural cardioactive pentacyclic hydroquinone from the sponge *Petrosia seriata*.  
*Comp. Biochem. Physiol.* 122c,93-99

17. Kobayashi M, Muroyama, Nakamura H, Kobayashi J, Ohizumi Y. 1991 Apr Xestoquinone, a novel cardiotonic agent activates actomyosin ATPase to enhance contractibility of skinned cardiac or skeletal muscle fibres. *J Pharmacol Exp Ther.*,257(1):90-4
18. Kobayashi M, Nakamura H, Kobayashi J, Ohizumi Y. 1991 Apr, Mech of inotropic action of Xestoquinone, a novel cardiotonic agent isolated from a sea sponge. *J Pharmacol Exp Ther.*,257(1):82-9.
19. Moran Y, Gordon D, Gurevitz M. Sea anemone toxins affecting voltage-gated sodium channels-molecular and evolutionary features. *Toxicon* 2009, 54(8): 1089-1101.
20. Erspamer, V.,1948. Active substance in the posterior salivary glands of octopoda. 2. Tyramine and Octopamine (oxyoctopamine) "Active substances in the posterior salivary glands of octopoda. II. Tyramine and Octopamine (Oxyoctopamine)". *Acta Pharmacologica et Toxicologica* 4 (3-4):224-247.